BioXyTran
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
BioXyTran - overview
Established
2018
Location
Needham, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2018 by co-founder David Platt, BioXyTran is firm developing drugs for the treatment of hypoxia, brain and heart ischemia, and viral infections like coronavirus and influenza. In June 2023, Triton Funds acquired 1,612,903 shares in BioXyTran for USD 500 thousand, or USD 0. 31 per share, in a PIPE transaction. The company offers BioXyTranTM, an oxygen carrier designed to enhance oxygen delivery to vital organs and tissues.
By leveraging glycan-based technology, BioXyTran treats oxygen deprivation-related conditions such as stroke, heart attack, and traumatic brain injuries. The company's product pipeline includes ProLectin and BXT.
Current Investors
Triton Funds
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.bioxytraninc.com
Verticals
Manufacturing
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
BioXyTran - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 417,336 | 275,616 | 255,822 | 246,495 | 191,077 | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | (34.0%) | (7.2%) | (3.6%) | (22.5%) | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (1,921,423) | (1,222,510) | (2,037,549) | (643,651) | (293,051) | (209,537) | (1,446,304) | (1,009,644) | (4,137,403) | (1,818,037) | - | - | - |
| Operating Income (USD) | (1,972,480) | (1,280,701) | (2,092,329) | (671,279) | (310,587) | (214,710) | (1,631,467) | (1,268,701) | (4,214,434) | (2,134,112) | - | - | - |
| Operating Margin | (472.6%) | (464.7%) | (817.9%) | (272.3%) | (162.5%) | - | - | - | - | - | - | - | - |
| % EBITDA Margin | (460.4%) | (443.6%) | (796.5%) | (261.1%) | (153.4%) | - | - | - | - | - | - | - | - |
| NET Income (USD) | (1,778,536) | (1,346,900) | (2,100,129) | (696,756) | (318,387) | (296,417) | (1,858,476) | (2,542,527) | (4,528,042) | (2,657,304) | - | - | - |
| % Net Margin | (426.2%) | (488.7%) | (820.9%) | (282.7%) | (166.6%) | - | - | - | - | - | - | - | - |
BioXyTran - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | BioXyTran | - | ||||||||
| PIPE | Completed | BioXyTran | - |
Displaying 1 - 2 of 2
BioXyTran - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.